JPMorgan Chase & Co. Purchases New Position in Enzo Biochem, Inc. (ENZ)

JPMorgan Chase & Co. purchased a new stake in Enzo Biochem, Inc. (NYSE:ENZ) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 24,677 shares of the medical research company’s stock, valued at approximately $263,000.

A number of other hedge funds have also recently made changes to their positions in ENZ. Dimensional Fund Advisors LP lifted its stake in Enzo Biochem by 10.5% in the second quarter. Dimensional Fund Advisors LP now owns 2,026,647 shares of the medical research company’s stock valued at $22,376,000 after acquiring an additional 193,246 shares during the last quarter. TIAA CREF Investment Management LLC lifted its stake in Enzo Biochem by 43.9% in the second quarter. TIAA CREF Investment Management LLC now owns 533,923 shares of the medical research company’s stock valued at $5,895,000 after acquiring an additional 162,854 shares during the last quarter. ClariVest Asset Management LLC lifted its stake in Enzo Biochem by 55.8% in the third quarter. ClariVest Asset Management LLC now owns 414,898 shares of the medical research company’s stock valued at $4,344,000 after acquiring an additional 148,578 shares during the last quarter. Evermore Global Advisors LLC lifted its stake in Enzo Biochem by 3.7% in the third quarter. Evermore Global Advisors LLC now owns 3,685,520 shares of the medical research company’s stock valued at $38,587,000 after acquiring an additional 130,287 shares during the last quarter. Finally, Mckinley Capital Management LLC Delaware lifted its stake in Enzo Biochem by 39.8% in the second quarter. Mckinley Capital Management LLC Delaware now owns 455,042 shares of the medical research company’s stock valued at $5,024,000 after acquiring an additional 129,538 shares during the last quarter. Hedge funds and other institutional investors own 63.65% of the company’s stock.

In other news, EVP James Michael O’brien sold 22,866 shares of the firm’s stock in a transaction dated Friday, October 27th. The shares were sold at an average price of $10.28, for a total transaction of $235,062.48. Following the completion of the sale, the executive vice president now owns 34,886 shares in the company, valued at approximately $358,628.08. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Gregory M. Bortz sold 42,005 shares of Enzo Biochem stock in a transaction dated Tuesday, October 31st. The stock was sold at an average price of $9.82, for a total transaction of $412,489.10. Following the completion of the sale, the director now owns 292,875 shares of the company’s stock, valued at approximately $2,876,032.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 191,398 shares of company stock valued at $1,925,292. 8.90% of the stock is currently owned by corporate insiders.

Shares of Enzo Biochem, Inc. (NYSE:ENZ) opened at $7.79 on Friday. The stock has a market cap of $363.67, a PE ratio of -259.67 and a beta of 0.87. Enzo Biochem, Inc. has a 12 month low of $6.27 and a 12 month high of $12.04.

Enzo Biochem (NYSE:ENZ) last posted its earnings results on Thursday, December 7th. The medical research company reported ($0.01) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.01). The company had revenue of $27.68 million during the quarter, compared to analysts’ expectations of $27.51 million. Enzo Biochem had a negative net margin of 1.53% and a negative return on equity of 1.89%. equities research analysts forecast that Enzo Biochem, Inc. will post -0.02 earnings per share for the current year.

Separately, TheStreet cut shares of Enzo Biochem from a “b” rating to a “c+” rating in a research note on Wednesday, September 27th.

TRADEMARK VIOLATION WARNING: “JPMorgan Chase & Co. Purchases New Position in Enzo Biochem, Inc. (ENZ)” was reported by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/3145434/jpmorgan-chase-co-purchases-new-position-in-enzo-biochem-inc-enz.html.

Enzo Biochem Company Profile

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Want to see what other hedge funds are holding ENZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enzo Biochem, Inc. (NYSE:ENZ).

Institutional Ownership by Quarter for Enzo Biochem (NYSE:ENZ)

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.